| Not Yet Recruiting | Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disea NCT07217028 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Withdrawn | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Meta NCT06603155 | Duke University | N/A |
| Recruiting | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Nec NCT06868433 | Emory University | Phase 1 |
| Recruiting | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returni NCT06589804 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058 | Emory University | N/A |
| Recruiting | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line P NCT06788990 | Bicara Therapeutics | Phase 2 / Phase 3 |
| Recruiting | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab NCT06782555 | ImmunoGenesis | Phase 1 / Phase 2 |
| Recruiting | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, NCT06636734 | Emory University | Phase 2 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC NCT06239220 | Glenn J. Hanna | Phase 2 |
| Recruiting | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV N NCT06064877 | AVEO Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Rec NCT06211335 | University of California, Davis | Phase 1 |
| Active Not Recruiting | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carci NCT05980000 | Washington University School of Medicine | Phase 2 |
| Withdrawn | Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Can NCT03875053 | Barbara Ann Karmanos Cancer Institute | N/A |
| Active Not Recruiting | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the NCT05721755 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Recruiting | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinom NCT05747625 | Eben Rosenthal | Phase 1 |
| Active Not Recruiting | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy NCT05063552 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Withdrawn | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squam NCT05359692 | Incyte Biosciences International Sàrl | Phase 2 |
| Recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) NCT05172258 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcin NCT04862650 | Marcelo Bonomi | Phase 2 |
| Recruiting | Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurren NCT05047094 | Alpha Tau Medical LTD. | N/A |
| Active Not Recruiting | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carc NCT04831320 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic NCT04643379 | Washington University School of Medicine | Phase 2 |
| Completed | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC NCT05156970 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Terminated | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamo NCT04862455 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition NCT04454489 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing NCT04305795 | Rakuten Medical, Inc. | Phase 1 / Phase 2 |
| Recruiting | Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer NCT04375384 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC NCT03813836 | University College, London | Phase 2 |
| Terminated | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat NCT03823131 | Chase Heaton, MD | Phase 2 |
| Completed | Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Me NCT03868020 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Completed | Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Ne NCT03575949 | M.D. Anderson Cancer Center | N/A |
| Terminated | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metasta NCT03522584 | University of Washington | Phase 1 / Phase 2 |
| Terminated | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or S NCT02449681 | Rain Oncology Inc | Phase 2 |
| Terminated | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT01602315 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma NCT02119559 | University Hospital, Montpellier | N/A |
| Active Not Recruiting | Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Nec NCT01468896 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent NCT00494182 | M.D. Anderson Cancer Center | Phase 2 |